Jasper scraps piv­otal plans but adds a new in­di­ca­tion as more biotechs re­vise pipelines

A suite of bio­phar­mas dis­closed cuts to their pipelines this week as the in­dus­try gets a sweep­ing up­date of drugs in the works as part of the an­nu­al JP Mor­gan Health­care Con­fer­ence.

Jasper Ther­a­peu­tics, Ac­ti­cor Biotech, NGM Bio and An­nex­on were among those to slash parts of their de­vel­op­ment plans.

The moves fol­low a rough 2022 for the mar­ket, in which dozens of biotechs shift­ed pri­or­i­ties to con­serve cash and stay afloat. Bio­phar­mas rou­tine­ly fine-tune their pipelines, but the con­sis­ten­cy of culls and lay­offs last year stood out.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER